Peter W Kalivas Selected Research

Acetylcysteine (Siran)

1/2022	The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.
1/2020	N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial.
1/2019	Targeting redox regulation to treat substance use disorder using N‐acetylcysteine
1/2019	Reply to: N-Acetylcysteine in Treatment of Substance Use Disorders.
11/2016	A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders.
3/2016	Corticostriatal circuitry in regulating diseases characterized by intrusive thinking.
1/2015	Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.
2/2014	Potential role of N-acetylcysteine in the management of substance use disorders.
9/2013	The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy.
9/2013	A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter W Kalivas Research Topics

Disease

26	Substance-Related Disorders (Drug Abuse) 01/2022 - 08/2008
12	Cocaine-Related Disorders (Cocaine Addiction) 01/2019 - 02/2004
4	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 06/2020
3	Anxiety Disorders (Anxiety Disorder) 01/2022 - 05/2009
3	Schizophrenia (Dementia Praecox) 01/2022 - 12/2005
3	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 06/2020 - 11/2016
2	Alcoholism (Alcohol Abuse) 01/2020 - 06/2006
2	Gambling (Pathological Gambling) 03/2016 - 02/2012
2	Tobacco Use Disorder (Nicotine Dependence) 01/2015 - 05/2009
1	Neurodevelopmental Disorders 01/2022
1	Chronic Pain 01/2022
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2022
1	Mental Disorders (Mental Disorder) 01/2022
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2022
1	Depressive Disorder (Melancholia) 01/2022
1	Psychotic Disorders (Schizoaffective Disorder) 11/2021
1	Hyperphagia (Overeating) 01/2020
1	Trichotillomania 03/2016
1	Heroin Dependence (Heroin Abuse) 11/2011
1	Cognitive Dysfunction 11/2009
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 05/2009
1	Cysts 10/2006
1	Epilepsy (Aura) 06/2006

Drug/Important Bio-Agent (IBA)

15	Pharmaceutical PreparationsIBA 01/2022 - 08/2008
14	Glutamic Acid (Glutamate)FDA Link 01/2022 - 02/2004
12	Acetylcysteine (Siran)FDA LinkGeneric 01/2022 - 03/2007
6	Cocaine (Cocaine HCl)IBA 11/2021 - 02/2006
3	AntioxidantsIBA 01/2022 - 10/2006
3	Opioid Analgesics (Opioids)IBA 01/2021 - 01/2015
2	Heroin (Diamorphine)IBA 01/2022 - 06/2020
2	Dopamine (Intropin)FDA LinkGeneric 11/2021 - 11/2009
2	EndocannabinoidsIBA 10/2020 - 01/2020
2	LigandsIBA 06/2014 - 02/2012
2	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 06/2014 - 08/2010
2	Cystine (L-Cystine)IBA 05/2009 - 10/2006
2	Protein Isoforms (Isoforms)IBA 06/2006 - 12/2005
1	Antipsychotic Agents (Antipsychotics)IBA 11/2021
1	OrexinsIBA 10/2020
1	Protons (Proton)IBA 01/2020
1	CannabinoidsIBA 01/2015
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2015
1	AmphetaminesIBA 01/2015
1	Nicotine FDA Link 01/2015
1	Ethanol (Ethyl Alcohol)IBA 01/2015
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 01/2015
1	Proteins (Proteins, Gene)FDA Link 06/2014
1	XanthineIBA 01/2014
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2011
1	Serotonin (5 Hydroxytryptamine)IBA 11/2009
1	Methamphetamine (Desoxyn)FDA LinkGeneric 11/2009
1	Carbon MonoxideIBA 05/2009
1	Biological ProductsIBA 03/2007
1	Glutathione (Reduced Glutathione)IBA 10/2006
1	latrunculin A (LAT-A)IBA 02/2006
1	Lim KinasesIBA 02/2006

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2015 - 03/2007
2	Self Administration (Administration, Self) 01/2021 - 06/2020